Loading…
Employees: 1,271
Size Hunan Er-Kang Pharmaceutical (300267.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $909M, the 2492nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥2.94 on 6 Nov 2026.
Performance Over six months the shares fell 32.6%, against -11.9% for the median peer and -16.4% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 14.4% over the last twelve months (peer median +1.3%); the operating margin is -29.2% (peer median 3.6%).
Valuation It trades at 5.2× enterprise value to sales against a peer median of 4.4× (7th most expensive of 18).
Capital Return on invested capital runs 11.6 points below its cost of capital (7.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.11B | CN¥1.16B | CN¥1.13B | CN¥1.77B | CN¥1.86B |
| Revenue growth | — | +2% | -36% | -5% | — |
| Gross profit | CN¥414M | CN¥242M | CN¥210M | CN¥241M | CN¥278M |
| EBITDA | n/a | CN¥140M | CN¥103M | -CN¥10.7M | CN¥172M |
| Net income | -CN¥347M | -CN¥380M | -CN¥373M | -CN¥195M | CN¥45.9M |
| Free cash flow | -CN¥161M | CN¥97.5M | -CN¥27.0M | -CN¥77.0M | CN¥121M |
| Capital expenditure | CN¥237M | CN¥164M | CN¥196M | CN¥238M | CN¥173M |
| Total debt | CN¥702M | CN¥602M | CN¥517M | CN¥363M | CN¥401M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300267.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.0% | -6.6% | 9th lowest of 20 |
| 6-month return | -32.6% | -11.9% | 3rd lowest of 20 |
| Distance from 52-week high | -42.5% | -33.9% | 6th lowest of 21 |
| Revenue growth (TTM) | -14.4% | +1.3% | 3rd lowest of 19 |
| Operating margin | -29.2% | 3.6% | 5th lowest of 19 |
| EV / Sales | 5.2× | 4.4× | 7th most expensive of 18 |
| ROIC minus cost of capital | -11.6 pp | -2.2 pp | 3rd lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | 5.2× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | 5.9× | -1.2% | -39.5% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | 2.9× | 16.2% | -0.2% |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 3.6× | 16.7% | +27.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 6.1× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | 7.1× | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | 4.3× | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | 15.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 4.4× | 33.2% | +4.2% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 5.1× | 16.2% | +27.3% |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | 57.5× | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 4.7× | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 0.7× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 2.1× | 2.5% | +12.4% |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | 1.0× | -6.8% | -0.7% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | 10.7× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 1.9× | 4.8% | +22.5% |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 0.9× | n/a | n/a |